华蟾素注射液联合TACE及微波消融治疗HBV感染的中晚期肝癌的近期疗效分析

Short-term Efficacy of Huachansu Injection Combined with TACE and Microwave Ablation in the Treatment of Advanced Hepatocellular Carcinoma with HBV Infection

目的探讨不能手术切除的HBV感染的中晚期肝癌行华蟾素注射液联合TACE及微波消融的近期疗效及不良反应。方法分析自2017年1月—2018年6月收治的不能手术切除的,伴有疼痛的HBV感染的肝癌病例56例,随机分为治疗组和对照组,治疗组和对照组均28例,治疗组行TACE及微波消融,联合华蟾素注射液治疗,对照组行TACE及微波消融,分析两组近期疗效和不良反应。结果治疗组原发灶的近期疗效与对照组相似,差异无统计学意义(χ2=0.42,P>0.05)。治疗组生活质量提高率为85.7%,对照组提高率为57.1%,治疗组优于对照组(P<0.05)。治疗组疼痛总缓解率为92.9%,对照组疼痛缓解率为67.9%,治疗组优于对照组(P<0.05)。两组相关不良反应相似(P>0.05)。结论对不能手术切除的,伴有疼痛的HBV感染的肝癌,TACE并微波消融,联合华蟾素注射液治疗,可显著改善患者的一般状况及控制疼痛,在改善生存质量方面具有一定的临床价值。

Objective To investigate the short-term efficacy and adverse reactions of Huachansu injection combined with TACE and microwave ablation in patients with advanced and unresectable HBV infection.Methods From January 2017 to June 2018,56 cases of unresectable liver cancer with painful HBV infection were randomly divided into treatment group and control group,28 cases in treatment group and control group each.TACE and microwave ablation were performed in combination with Huachansu injection in the treatment group.TACE and microwave ablation were performed in the control group.The short-term effects and adverse reactions were analyzed.Results The short-term efficacy of the primary tumor in the treatment group was similar to that of the control group.the difference was not statistically significant(χ2=0.42,P>0.05).The quality of life improvement rate was 85.7%in the treatment group and 57.1%in the control group.The treatment group was superior to the control group(P<0.05).The total pain relief rate was 92.9%in the treatment group and 67.9%in the control group.The treatment group was superior to the control group(P<0.05).The adverse events in the two groups were similar(P>0.05).Conclusion For patients with unresectable liver cancer with painful HBV infection,TACE and microwave ablation combined with Huachansu injection can significantly improve the general condition of patients and control pain,and have certain clinical value in improving the quality of life.